Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 3
2012 2
2013 1
2015 1
2016 1
2018 2
2020 1
2021 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
A PGE2-MEF2A axis enables context-dependent control of inflammatory gene expression.
Cilenti F, Barbiera G, Caronni N, Iodice D, Montaldo E, Barresi S, Lusito E, Cuzzola V, Vittoria FM, Mezzanzanica L, Miotto P, Di Lucia P, Lazarevic D, Cirillo DM, Iannacone M, Genua M, Ostuni R. Cilenti F, et al. Among authors: iodice d. Immunity. 2021 Aug 10;54(8):1665-1682.e14. doi: 10.1016/j.immuni.2021.05.016. Epub 2021 Jun 14. Immunity. 2021. PMID: 34129840 Free PMC article.
Loss of EMILIN-1 Enhances Arteriolar Myogenic Tone Through TGF-β (Transforming Growth Factor-β)-Dependent Transactivation of EGFR (Epidermal Growth Factor Receptor) and Is Relevant for Hypertension in Mice and Humans.
Carnevale D, Facchinello N, Iodice D, Bizzotto D, Perrotta M, De Stefani D, Pallante F, Carnevale L, Ricciardi F, Cifelli G, Da Ros F, Casaburo M, Fardella S, Bonaldo P, Innocenzi G, Rizzuto R, Braghetta P, Lembo G, Bressan GM. Carnevale D, et al. Among authors: iodice d. Arterioscler Thromb Vasc Biol. 2018 Oct;38(10):2484-2497. doi: 10.1161/ATVBAHA.118.311115. Arterioscler Thromb Vasc Biol. 2018. PMID: 30354220
Sarilumab plus standard of care vs standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE study).
Mastrorosa I, Gagliardini R, Segala FV, Mondi A, Lorenzini P, Cerva C, Taddei E, Bai F, Vergori A, Marcantonio N, Pinnetti C, Cicalini S, Murri R, Mazzotta V, Camici M, Mosti S, Bini T, Maffongelli G, Beccacece A, Milozzi E, Iannetta M, Lamonica S, Fusto M, Plazzi MM, Ottou S, Lichtner M, Fantoni M, Andreoni M, Sarmati L, Cauda R, Girardi E, Nicastri E, D'Arminio Monforte A, Palmieri F, Cingolani A, Vaia F, Antinori A; ESCAPE study group. Mastrorosa I, et al. EClinicalMedicine. 2023 Mar 10;57:101895. doi: 10.1016/j.eclinm.2023.101895. eCollection 2023 Mar. EClinicalMedicine. 2023. PMID: 36936403 Free PMC article.
12 results